Motilal Oswal's research report on Divi’s Laboratories
DIVI delivered a better-than-expected performance in 4QFY23, driven by improved traction in the generic API segment. The Custom Synthesis (CS) business also reported a slow uptick in sales. We raise our earnings estimates for FY24/FY25 by 7%/6% to factor in 1) a scale-up in commercial contracts in the CS segment, 2) a reduction in the availability of high-cost raw materials, and 3) improvement in operating leverage.
Outlook
We value divi at 30x 12M forward earnings to arrive at a TP of INR2,900. While the outlook is improving across segments of CS and generic APIs on the back of new launches and sharp focus on cost minimization, the current valuation adequately factors in the earnings upside. Hence, we maintain our Neutral rating on the stock.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
